INDV shorts ease as acquisition deal reshapes the register

Indivior Pharmaceuticals enters its October 29 earnings release with short sellers retreating, two activists on the register in different stages of exit, and a stock acquisition deal driving mechanical index flows across five benchmarks.

Short interest has fallen sharply over the past month. At 7.4% of the free float, the position is meaningful but no longer growing: shorts have covered roughly 11% of their position over the past week alone, and the 30-day drawdown in short shares is close to 16.5%. The drop came in a single step, with roughly one million shares covered between October 22 and October 23. Borrow conditions remain loose, with availability at nearly 1,099%, meaning there are more than eleven shares available to lend for every one already borrowed. Even with a 22% rise in the cost to borrow over the week, the absolute rate of 0.45% sits near the low end of its 30-day range. The ORTEX short score has tracked the covering: it fell from 52.8 on October 14 to 48.5 by October 27, crossing below the neutral midpoint and pointing to reduced bearish pressure in the lending market. Options positioning is similarly unexciting, with the put/call ratio at 0.996, almost exactly in line with its 20-day average and well within one standard deviation of normal.

The deal dominating the ownership picture is Indivior's agreed acquisition of Supernus Pharmaceuticals (SUPN), which explains both the activist register activity and the index rebalance forecasts. ORTEX puts the probability of a share-count increase in the FTSE Global Small index at 99%, with trade and effective dates estimated around November 2 and 3. Across the Russell 2000, Russell 3000, S&P SmallCap 600 and MSCI World Small, ORTEX puts the probability between 65% and 84%. These are forecasts, not confirmed announcements, but the FTSE Global Small row has moved to "decided" stage. The SUPN ticker itself moved in near-lockstep with INDV on Tuesday, down 0.65% on the week against INDV's 0.14% decline.

Two activists remain on the 13D register, a fact worth carrying into any read of ownership stability. Two Seas Capital filed a Schedule 13D/A in December 2025 and most recently disclosed a 4.98% stake, below the 5.7% it held previously. Oaktree Capital has moved further: its last 13D/A, filed in August 2026, showed a 0.76% position against a prior 5.69%, effectively a near-complete exit. As the ORTEX disclosure notes, 13D/G stakes are event-driven disclosures around the 5% threshold, and a holder who drops below 5% may exit without further filing. Millennium Management has been moving in the opposite direction: its September 30 filing showed a 5.4% stake, up from 3.8%, making it the freshest and most material institutional addition on the register. BlackRock, the largest holder at 15.9%, added 224,000 shares in the quarter to September 30. Franklin Templeton added 2.6 million shares in the same period, taking its position to 2.3% of shares.

The Street's analytical coverage is relatively thin and the most recent changes are dated. Barclays analyst Glen Santangelo cut the price target from $46 to $43 in August, maintaining an Overweight rating, the only action within the past six months from a major firm. The mean price target across covering analysts is $49.00, implying 41% upside to the current price of $34.72. The bull case centres on Sublocade volume growth, with patient numbers reportedly up 8% year-on-year to 171,500 and prescribers up 11% as of the third quarter of 2025. The bear case is the geographic narrowing of the commercial footprint, from roughly 40 countries to four, alongside an anticipated revenue decline of around 6.5% in 2026 as portfolio simplification flows through. On valuation, the stock trades at a trailing PE of 7.2 and an EV/EBITDA of 5.5, with an earnings yield ranking in the 94th percentile of its universe, a reading that reflects how cheaply the market is pricing the earnings stream. The EV/EBIT factor score sits at the 77th percentile.

Indivior declared a special cash dividend of $8.13 per share in September, payable on or about November 6, likely funded in part by the balance sheet ahead of the SUPN transaction. The Chief Accounting Officer made two open-market purchases in August, totalling 3,000 shares at prices around $35.69 to $36.28. The CFO's June sale of 36,000 shares was executed under a pre-arranged 10b5-1 plan, and the CSO's two sales in June and July were similarly plan-driven, reducing their signal value as a conviction indicator. The 90-day net insider position is a modest 70,000 shares negative on value, not a material directional read.

The October 29 earnings release, with the SUPN acquisition pending and index rebalance flows forecast for the first week of November, means the next few trading sessions carry more moving parts than a typical quarterly print.